AureoGen Biosciences, Inc. Company Presentation

1:15 PM–1:30 PM Jun 5, 2019 (US - Eastern)

Theater 3


AureoGen Biosciences is a Michigan based biotechnology company that develops novel antibiotics for indications with critically unmet medical needs. The company’s technology focus is on (modified) natural products. AureoGen’s current lead asset, AUGC-15, is a novel drug for the treatment of fungal infections. AUGC-15 is a first in class drug with a novel mode of action and none of the limitations associated with drugs in current clinical use. The compound is active against a wide range of fungal pathogens, including azole and echinocandin resistant strains. AUGC-15 is very well tolerated and can be administered both IV and PO. It also has excellent PK properties and proven efficacy in a mouse candidiasis model. AUGC-15 is a member of a family of related compounds all prepared using AureoGen’s proprietary chemistry. The compounds, as well as the chemistry, are protected by issued patents in the US, Canada, Japan and Australia. Patents in Europe and additional nations are pending

Session ID: 524292